MedPath

MEDREGEN LLC

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.medregenco.com/

Clinical Trials

7

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
7 (100.0%)

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Phase 2
Not yet recruiting
Conditions
Amyotrophic Lateral Sclerosis
Lou Gehrig Disease
Motor Neuron Disease
Motor Neuron Atrophy
Interventions
First Posted Date
2024-03-18
Last Posted Date
2024-08-23
Lead Sponsor
MedRegen LLC
Target Recruit Count
10
Registration Number
NCT06315608

MRG-001 in Patients With Alcoholic Hepatitis

Phase 2
Not yet recruiting
Conditions
Acute Alcoholic Hepatitis
Alcoholic Hepatitis
Interventions
First Posted Date
2024-03-13
Last Posted Date
2024-03-13
Lead Sponsor
MedRegen LLC
Target Recruit Count
32
Registration Number
NCT06307522

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Phase 2
Not yet recruiting
Conditions
Cytokine Storm
Acute Respiratory Distress Syndrome
Respiratory Failure
Respiratory Distress Syndrome
Respiratory Tract Diseases
Interventions
Drug: MRG-001 (High-dose)
Other: Placebo
Drug: MRG-001 (Low-dose)
First Posted Date
2024-03-13
Last Posted Date
2024-08-23
Lead Sponsor
MedRegen LLC
Target Recruit Count
60
Registration Number
NCT06308926

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Phase 2
Completed
Conditions
Abdominal Wound
Wound of Skin
Interventions
Drug: Saline
First Posted Date
2023-05-06
Last Posted Date
2025-09-08
Lead Sponsor
MedRegen LLC
Target Recruit Count
10
Registration Number
NCT05844527
Locations
πŸ‡ΊπŸ‡Έ

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Phase 2
Conditions
COVID-19
ARDS, Human
Stem Cells
Regeneration
Interventions
Drug: Placebo
First Posted Date
2020-11-30
Last Posted Date
2022-02-15
Lead Sponsor
MedRegen LLC
Target Recruit Count
40
Registration Number
NCT04646603
Locations
πŸ‡ΊπŸ‡Έ

Johns Hopkins Medicine, Baltimore, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.